Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.

M Prokocimer1, M Modan, S Rusoshansky

  • 1Hematology Division, Beilinson Medical Center, Petah Tiqva, Israel.

Anticancer Research
|July 1, 1989
PubMed
Summary

ProMACE CytaBOM chemotherapy led to complete remission in diffuse large cell lymphoma patients. This regimen shows promising long-term survival and remission probabilities with tolerable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Precise quantification of haemoglobin in erythroid precursors and plasma.

International journal of laboratory hematology·2011
Same author

Butyrate-induced differentiation in leukemic myeloid cells - in-vitro and in-vivo studies.

International journal of oncology·2011
Same author

Contents page format in scientific journals - effect on efficiency and ease of scanning.

Methods of information in medicine·2011
Same author

Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells.

International journal of laboratory hematology·2009
Same author

The added value of peripheral blood cell morphology in the diagnosis and management of infectious diseases--part 1: basic concepts.

Postgraduate medical journal·2008

Area of Science:

  • Oncology
  • Hematology
  • Clinical Pharmacology

Background:

  • Diffuse large cell lymphoma (DLCL) is an aggressive non-Hodgkin's lymphoma.
  • Effective and tolerable chemotherapy regimens are crucial for DLCL treatment.
  • Previous treatment strategies have varying success rates and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of the ProMACE CytaBOM polychemotherapy regimen.
  • To assess complete remission (CR) rates and long-term outcomes in DLCL patients.
  • To compare ProMACE CytaBOM with existing treatment protocols.

Main Methods:

  • A consecutive series of six DLCL patients received ProMACE CytaBOM outpatient chemotherapy.
  • The regimen includes cyclophosphamide, doxorubicin, etoposide, bleomycin, vincristine, methotrexate, and prednisone.

Related Experiment Videos

  • Outcomes assessed included CR, relapse rates, survival, and side effects.

    • Main Results:

    • All six patients achieved a complete remission (CR) after ProMACE CytaBOM treatment.
    • Actuarial analysis predicted a 66.7% survival and 62.5% probability of remaining in remission at 40 months.
    • Tolerable side effects included peripheral neuropathy, infections, and mucositis.

    Conclusions:

    • ProMACE CytaBOM is a highly effective chemotherapy regimen for diffuse large cell lymphoma.
    • The regimen demonstrates favorable long-term remission and survival probabilities.
    • ProMACE CytaBOM is an easy-to-administer outpatient treatment option with manageable side effects.